Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in a notoriously deadly and intractable malignancy.  Patients who took the daily pill, called daraxonrasib, lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy. It’s “very impressive,” said Benjamin Weinberg, an associate professor of medicine at Georgetown University who was not involved in the study, in an email. Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 13 Apr 2026.
The item focuses on STAT+: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill.
Review the original article for the full source wording and details.